Thyroid Hormones, Peripheral White Blood Count, and Dose of Basal Insulin Are Associated with Changes in Nerve Conduction Studies in Adolescents with Type 1 Diabetes
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Statistical Analysis
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Feldman, E.L.; Callaghan, B.C.; Pop-Busui, R.; Zochodne, D.W.; Wright, D.E.; Bennett, D.L.; Bril, V.; Russell, J.W.; Viswanathan, V. Diabetic Neuropathy. Nat. Rev. Dis. Primers 2019, 5, 42. [Google Scholar] [CrossRef] [PubMed]
- IDF Diabetes Atlas, Tenth Edition. Available online: https://diabetes.atlas.org (accessed on 20 October 2021).
- Tabish, S.A. Is Diabetes Becoming the Biggest Epidemic of the Twenty-First Century? Int. J. Health Sci. 2007, 1, V–VIII. [Google Scholar]
- Diabetes. Available online: https://www.who.int/news-room/fact-sheets/detail/diabetes (accessed on 3 November 2021).
- Boulton, A.J.M.; Vinik, A.I.; Arezzo, J.C.; Bril, V.; Feldman, E.L.; Freeman, R.; Malik, R.A.; Maser, R.E.; Sosenko, J.M.; Ziegler, D.; et al. Diabetic Neuropathies: A Statement by the American Diabetes Association. Diabetes Care 2005, 28, 956–962. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mah, J.K.; Pacaud, D. Diabetic Neuropathy in Children. Handb. Clin. Neurol. 2014, 126, 123–143. [Google Scholar] [CrossRef]
- Tesfaye, S.; Boulton, A.J.M.; Dyck, P.J.; Freeman, R.; Horowitz, M.; Kempler, P.; Lauria, G.; Malik, R.A.; Spallone, V.; Vinik, A.; et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care 2010, 33, 2285–2293. [Google Scholar] [CrossRef] [Green Version]
- Hendriksen, P.H.; Oey, P.L.; Wieneke, G.H.; Bravenboer, B.; van Huffelen, A.C. Subclinical Diabetic Polyneuropathy: Early Detection of Involvement of Different Nerve Fibre Types. J. Neurol. Neurosurg. Psychiatry 1993, 56, 509–514. [Google Scholar] [CrossRef] [Green Version]
- Wysocka-Mincewicz, M.; Emeryk-Szajewska, B.; Trippenbach-Dulska, M.; Pańkowska, E.; Zajączkowska, J. Prevalence of diabetic polyneuropathy in children with type 1 diabetes. Pediatr. Diab. 2005, 6 (Suppl. 3), s27. [Google Scholar]
- Piontek, E.; Wysocka-Mincewicz, M.; Gromek, I.; Skwarzec, J. Does motor nerves impairment predominate in children with short duration type 1 diabetes and poor metabolic control? Diabetologia 2007, 50 (Suppl. 1), S443. [Google Scholar]
- Papanas, N.; Ziegler, D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Rev. Diabet. Stud. 2015, 12, 48–62. [Google Scholar] [CrossRef] [Green Version]
- Diabetes Control and Complications Trial Research Group; Nathan, D.M.; Genuth, S.; Lachin, J.; Cleary, P.; Crofford, O.; Davis, M.; Rand, L.; Siebert, C. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977–986. [Google Scholar] [CrossRef]
- Christensen, M.M.B.; Hommel, E.E.; Jørgensen, M.E.; Fleischer, J.; Hansen, C.S. Glycemic Variability and Diabetic Neuropathy in Young Adults With Type 1 Diabetes. Front. Endocrinol. 2020, 11, 644. [Google Scholar] [CrossRef]
- Callaghan, B.C.; Gao, L.; Li, Y.; Zhou, X.; Reynolds, E.; Banerjee, M.; Pop-Busui, R.; Feldman, E.L.; Ji, L. Diabetes and Obesity Are the Main Metabolic Drivers of Peripheral Neuropathy. Ann. Clin. Transl. Neurol. 2018, 5, 397–405. [Google Scholar] [CrossRef]
- Callaghan, B.C.; Xia, R.; Banerjee, M.; de Rekeneire, N.; Harris, T.B.; Newman, A.B.; Satterfield, S.; Schwartz, A.V.; Vinik, A.I.; Feldman, E.L.; et al. Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status. Diabetes Care 2016, 39, 801–807. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Callaghan, B.C.; Xia, R.; Reynolds, E.; Banerjee, M.; Rothberg, A.E.; Burant, C.F.; Villegas-Umana, E.; Pop-Busui, R.; Feldman, E.L. Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. JAMA Neurol. 2016, 73, 1468–1476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanewinckel, R.; Drenthen, J.; Ligthart, S.; Dehghan, A.; Franco, O.H.; Hofman, A.; Ikram, M.A.; van Doorn, P.A. Metabolic Syndrome Is Related to Polyneuropathy and Impaired Peripheral Nerve Function: A Prospective Population-Based Cohort Study. J. Neurol. Neurosurg. Psychiatry 2016, 87, 1336–1342. [Google Scholar] [CrossRef] [PubMed]
- Tesfaye, S.; Selvarajah, D. The Eurodiab Study: What Has This Taught Us about Diabetic Peripheral Neuropathy? Curr. Diab. Rep. 2009, 9, 432–434. [Google Scholar] [CrossRef] [PubMed]
- Tesfaye, S.; Chaturvedi, N.; Eaton, S.E.M.; Ward, J.D.; Manes, C.; Ionescu-Tirgoviste, C.; Witte, D.R.; Fuller, J.H.; EURODIAB Prospective Complications Study Group. Vascular Risk Factors and Diabetic Neuropathy. N. Engl. J. Med. 2005, 352, 341–350. [Google Scholar] [CrossRef] [Green Version]
- Nordwall, M.; Arnqvist, H.J.; Bojestig, M.; Ludvigsson, J. Good Glycemic Control Remains Crucial in Prevention of Late Diabetic Complications--the Linköping Diabetes Complications Study. Pediatr. Diabetes 2009, 10, 168–176. [Google Scholar] [CrossRef]
- Tesfaye, S.; Stevens, L.K.; Stephenson, J.M.; Fuller, J.H.; Plater, M.; Ionescu-Tirgoviste, C.; Nuber, A.; Pozza, G.; Ward, J.D. Prevalence of Diabetic Peripheral Neuropathy and Its Relation to Glycaemic Control and Potential Risk Factors: The EURODIAB IDDM Complications Study. Diabetologia 1996, 39, 1377–1384. [Google Scholar] [CrossRef]
- Adler, A.I.; Boyko, E.J.; Ahroni, J.H.; Stensel, V.; Forsberg, R.C.; Smith, D.G. Risk Factors for Diabetic Peripheral Sensory Neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997, 20, 1162–1167. [Google Scholar] [CrossRef]
- Shaw, J.E.; Hodge, A.M.; de Courten, M.; Dowse, G.K.; Gareeboo, H.; Tuomilehto, J.; Alberti, K.G.; Zimmet, P.Z. Diabetic Neuropathy in Mauritius: Prevalence and Risk Factors. Diabetes Res. Clin. Pract. 1998, 42, 131–139. [Google Scholar] [CrossRef]
- Liu, X.; Xu, Y.; An, M.; Zeng, Q. The Risk Factors for Diabetic Peripheral Neuropathy: A Meta-Analysis. PLoS ONE 2019, 14, e0212574. [Google Scholar] [CrossRef] [PubMed]
- Feldman, E.L.; Nave, K.-A.; Jensen, T.S.; Bennett, D.L.H. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron 2017, 93, 1296–1313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rumora, A.E.; Lentz, S.I.; Hinder, L.M.; Jackson, S.W.; Valesano, A.; Levinson, G.E.; Feldman, E.L. Dyslipidemia Impairs Mitochondrial Trafficking and Function in Sensory Neurons. FASEB J. 2018, 32, 195–207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, V.P.; Bali, A.; Singh, N.; Jaggi, A.S. Advanced Glycation End Products and Diabetic Complications. Korean J. Physiol. Pharmacol. 2014, 18, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Padilla, A.; Descorbeth, M.; Almeyda, A.L.; Payne, K.; De Leon, M. Hyperglycemia Magnifies Schwann Cell Dysfunction and Cell Death Triggered by PA-Induced Lipotoxicity. Brain Res. 2011, 1370, 64–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martin, C.L.; Albers, J.W.; Pop-Busui, R.; DCCT/EDIC Research Group. Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2014, 37, 31–38. [Google Scholar] [CrossRef] [Green Version]
- Ziegler, D.; Behler, M.; Schroers-Teuber, M.; Roden, M. Near-Normoglycaemia and Development of Neuropathy: A 24-Year Prospective Study from Diagnosis of Type 1 Diabetes. BMJ Open 2015, 5, e006559. [Google Scholar] [CrossRef]
- Ziegler, D.; Papanas, N.; Vinik, A.I.; Shaw, J.E. Epidemiology of Polyneuropathy in Diabetes and Prediabetes. Handb. Clin. Neurol. 2014, 126, 3–22. [Google Scholar] [CrossRef]
- Factors in Development of Diabetic Neuropathy. Baseline Analysis of Neuropathy in Feasibility Phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 1988, 37, 476–481. [Google Scholar] [CrossRef]
- Hyllienmark, L.; Brismar, T.; Ludvigsson, J. Subclinical Nerve Dysfunction in Children and Adolescents with IDDM. Diabetologia 1995, 38, 685–692. [Google Scholar] [CrossRef] [PubMed]
- Bjornstad, P.; Snell-Bergeon, J.K.; Nadeau, K.J.; Maahs, D.M. Insulin Sensitivity and Complications in Type 1 Diabetes: New Insights. World J. Diabetes 2015, 6, 8–16. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.O.; Nam, J.S.; Ahn, C.W.; Hong, J.-M.; Kim, S.-M.; Sunwoo, I.-N.; Moon, J.-S.; Na, S.-J.; Choi, Y.-C. Insulin Resistance Is Independently Associated with Peripheral and Autonomic Neuropathy in Korean Type 2 Diabetic Patients. Acta Diabetol. 2012, 49, 97–103. [Google Scholar] [CrossRef] [PubMed]
- Cho, Y.N.; Lee, K.O.; Jeong, J.; Park, H.J.; Kim, S.M.; Shin, H.Y.; Hong, J.M.; Ahn, C.W.; Choi, Y.C. The Role of Insulin Resistance in Diabetic Neuropathy in Koreans with Type 2 Diabetes Mellitus: A 6-Year Follow-up Study. Yonsei Med. J. 2014, 55, 700–708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Falkowski, B.; Rogowicz-Frontczak, A.; Grzelka, A.; Uruska, A.; Schlaffke, J.; Araszkiewicz, A.; Zozulinska-Ziolkiewicz, D. Higher Free Triiodothyronine Concentration Is Associated with Lower Prevalence of Microangiopathic Complications and Better Metabolic Control in Adult Euthyroid People with Type 1 Diabetes. Endocrine 2018, 60, 458–465. [Google Scholar] [CrossRef] [Green Version]
- Zhao, W.; Zeng, H.; Zhang, X.; Liu, F.; Pan, J.; Zhao, J.; Zhao, J.; Li, L.; Bao, Y.; Liu, F.; et al. A High Thyroid Stimulating Hormone Level Is Associated with Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients. Diabetes Res. Clin. Pract. 2016, 115, 122–129. [Google Scholar] [CrossRef]
- Zhu, F.-F.; Yang, L.-Z. The Association Between the Levels of Thyroid Hormones and Peripheral Nerve Conduction in Patients with Type 2 Diabetes Mellitus. Exp. Clin. Endocrinol. Diabetes 2018, 126, 493–504. [Google Scholar] [CrossRef]
- LU, M.; YANG, C.-B.; GAO, L.; ZHAO, J.-J. Mechanism of Subclinical Hypothyroidism Accelerating Endothelial Dysfunction (Review). Exp. Ther. Med. 2015, 9, 3–10. [Google Scholar] [CrossRef] [Green Version]
- Schmidt, M.I.; Duncan, B.B.; Sharrett, A.R.; Lindberg, G.; Savage, P.J.; Offenbacher, S.; Azambuja, M.I.; Tracy, R.P.; Heiss, G. Markers of Inflammation and Prediction of Diabetes Mellitus in Adults (Atherosclerosis Risk in Communities Study): A Cohort Study. Lancet 1999, 353, 1649–1652. [Google Scholar] [CrossRef]
- Vozarova, B.; Weyer, C.; Lindsay, R.S.; Pratley, R.E.; Bogardus, C.; Tataranni, P.A. High White Blood Cell Count Is Associated with a Worsening of Insulin Sensitivity and Predicts the Development of Type 2 Diabetes. Diabetes 2002, 51, 455–461. [Google Scholar] [CrossRef] [Green Version]
- Ford, E.S. Leukocyte Count, Erythrocyte Sedimentation Rate, and Diabetes Incidence in a National Sample of US Adults. Am. J. Epidemiol. 2002, 155, 57–64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ohshita, K.; Yamane, K.; Hanafusa, M.; Mori, H.; Mito, K.; Okubo, M.; Hara, H.; Kohno, N. Elevated White Blood Cell Count in Subjects with Impaired Glucose Tolerance. Diabetes Care 2004, 27, 491–496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Danesh, J.; Collins, R.; Appleby, P.; Peto, R. Association of Fibrinogen, C-Reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease Meta-Analyses of Prospective Studies. JAMA 1998, 279, 1477–1482. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.D.; Folsom, A.R.; Nieto, F.J.; Chambless, L.E.; Shahar, E.; Wolfe, D.A. White Blood Cell Count and Incidence of Coronary Heart Disease and Ischemic Stroke and Mortality from Cardiovascular Disease in African-American and White Men and Women: Atherosclerosis Risk in Communities Study. Am. J. Epidemiol. 2001, 154, 758–764. [Google Scholar] [CrossRef]
- Cavalot, F.; Massucco, P.; Perna, P.; Traversa, M.; Anfossi, G.; Trovati, M. White Blood Cell Count Is Positively Correlated with Albumin Excretion Rate in Subjects with Type 2 Diabetes. Diabetes Care 2002, 25, 2354–2355. [Google Scholar] [CrossRef] [Green Version]
- Tong, P.C.; Lee, K.-F.; So, W.-Y.; Ng, M.H.; Chan, W.-B.; Lo, M.K.; Chan, N.N.; Chan, J.C. White Blood Cell Count Is Associated with Macro- and Microvascular Complications in Chinese Patients with Type 2 Diabetes. Diabetes Care 2004, 27, 216–222. [Google Scholar] [CrossRef] [Green Version]
- Chung, F.-M.; Tsai, J.C.-R.; Chang, D.-M.; Shin, S.-J.; Lee, Y.-J. Peripheral Total and Differential Leukocyte Count in Diabetic Nephropathy: The Relationship of Plasma Leptin to Leukocytosis. Diabetes Care 2005, 28, 1710–1717. [Google Scholar] [CrossRef] [Green Version]
- Yue, S.; Zhang, J.; Wu, J.; Teng, W.; Liu, L.; Chen, L. Use of the Monocyte-to-Lymphocyte Ratio to Predict Diabetic Retinopathy. Int. J. Environ. Res. Public Health 2015, 12, 10009. [Google Scholar] [CrossRef]
- Karatas, A.; Turkmen, E.; Erdem, E.; Dugeroglu, H.; Kaya, Y. Monocyte to High-Density Lipoprotein Cholesterol Ratio in Patients with Diabetes Mellitus and Diabetic Nephropathy. Biomark. Med. 2018, 12, 953–959. [Google Scholar] [CrossRef]
- Yang, L.; Hu, J.; Wang, Z.; Chen, X.; Wang, Y.; Yang, S.; Luo, T.; Mei, M.; Cheng, Q.; Xu, Z.; et al. Peripheral Monocyte Count Is an Independent Predictor of All-Cause Mortality in Type 2 Diabetes with Macro-Vascular Complications. Medicine 2020, 99, e18876. [Google Scholar] [CrossRef]
- Vural, G.; Gümüsyayla, Ş. Monocyte-to-High Density Lipoprotein Ratio Is Associated with a Decreased Compound Muscle Action Potential Amplitude in Patients with Diabetic Axonal Polyneuropathy. Medicine 2018, 97, e12857. [Google Scholar] [CrossRef]
- Yilmaz, H.; Ucan, B.; Sayki, M.; Unsal, I.; Sahin, M.; Ozbek, M.; Delibasi, T. Usefulness of the Neutrophil-to-Lymphocyte Ratio to Prediction of Type 2 Diabetes Mellitus in Morbid Obesity. Diabetol. Metab. Syndr. 2015, 9, 299–304. [Google Scholar] [CrossRef]
- Liu, S.; Zheng, H.; Zhu, X.; Mao, F.; Zhang, S.; Shi, H.; Li, Y.; Lu, B. Neutrophil-to-Lymphocyte Ratio Is Associated with Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients. Diabetes Res. Clin. Pract. 2017, 130, 90–97. [Google Scholar] [CrossRef] [PubMed]
- Traveset, A.; Rubinat, E.; Ortega, E.; Alcubierre, N.; Vazquez, B.; Hernández, M.; Jurjo, C.; Espinet, R.; Ezpeleta, J.A.; Mauricio, D. Lower Hemoglobin Concentration Is Associated with Retinal Ischemia and the Severity of Diabetic Retinopathy in Type 2 Diabetes. J. Diabetes Res. 2016, 2016, 3674946. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Okada, H.; Hasegawa, G.; Tanaka, M.; Osaka, T.; Shiotsu, Y.; Narumiya, H.; Inoue, M.; Nakano, K.; Nakamura, N.; Fukui, M. Association between Hemoglobin Concentration and the Progression or Development of Albuminuria in Diabetic Kidney Disease. PLoS ONE 2015, 10, e0129192. [Google Scholar] [CrossRef] [Green Version]
- Niu, Y.; Li, J.; Peng, R.; Zhao, X.; Wu, J.; Tang, Q. Low Vitamin D Is Associated with Diabetes Peripheral Neuropathy in Older but Not in Young and Middle-Aged Patients. Diabetes Metab. Res. Rev. 2019, 35, e3162. [Google Scholar] [CrossRef]
- Young, M.J.; Boulton, A.J.; MacLeod, A.F.; Williams, D.R.; Sonksen, P.H. A Multicentre Study of the Prevalence of Diabetic Peripheral Neuropathy in the United Kingdom Hospital Clinic Population. Diabetologia 1993, 36, 150–154. [Google Scholar] [CrossRef] [Green Version]
- Meijer, J.W.G.; Smit, A.J.; Sonderen, E.V.; Groothoff, J.W.; Eisma, W.H.; Links, T.P. Symptom Scoring Systems to Diagnose Distal Polyneuropathy in Diabetes: The Diabetic Neuropathy Symptom Score. Diabet. Med. 2002, 19, 962–965. [Google Scholar] [CrossRef] [Green Version]
- Cole, T.J. The Development of Growth References and Growth Charts. Ann. Hum. Biol. 2012, 39, 382–394. [Google Scholar] [CrossRef] [Green Version]
- Cole, T.J.; Green, P.J. Smoothing Reference Centile Curves: The LMS Method and Penalized Likelihood. Stat. Med. 1992, 11, 1305–1319. [Google Scholar] [CrossRef]
- Kułaga, Z.; Litwin, M.; Tkaczyk, M.; Palczewska, I.; Zajączkowska, M.; Zwolińska, D.; Krynicki, T.; Wasilewska, A.; Moczulska, A.; Morawiec-Knysak, A.; et al. Polish 2010 Growth References for School-Aged Children and Adolescents. Eur. J. Pediatr. 2011, 170, 599–609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kułaga, Z.; Grajda, A.; Gurzkowska, B.; Góźdź, M.; Wojtyło, M.; Świąder, A.; Różdżyńska-Świątkowska, A.; Litwin, M. Polish 2012 Growth References for Preschool Children. Eur. J. Pediatr. 2013, 172, 753–761. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Median Motor Nerve | Tibial Posterior Nerve | |
---|---|---|
Motor conduction velocity (MCV) | R = 0.38, R2 = 0.15, p < 0.0005 Height ß = 0.25, p = 0.07 Weight ß = −0.34, p < 0.02 BMI Z-score ß = −2.95, p < 0.05 BID/kg ß = −9.37, p = 0.09 HbA1c mean ß = −1.05, p < 0.001 Duration of CSII ß = −0.49, p < 0.001 NLR ß = −0.31, p = 0.5 | R = 0.56, R2 = 0.31, p < 0.00000 Height ß = −0.023, p < 0.0001 Total Hb ß = 1.27, p < 0.01 MCHC ß = −1.94, p < 0.0001 BID/kg ß = −11.17, p < 0.05 HbA1c mean ß = −0.7, p = 0.1 Monocytes ß = −1.38, p = 0.6 |
Distal motor latency (DML) | R = 0.39, R2 = 0.15, p < 0.001 Height ß = 0.09, p < 0.005 Weight ß = −0.1, p < 0.02 BMI ß = −0.33, p < 0.001 BID/kg ß = −1.03, p < 0.05 WBC ß = −0.15, p < 0.05 Duration of CSII ß = −0.12, p = 0.4 NLR ß = −0.22, p = 0.15 | R = 0.36, R2 = 0.13, p < 0.0005 HbA1c mean ß = 0.11, p < 0.003 Weight ß = 0.021, p < 0.005 BMI ß = −0.8, p < 0.005 TDI/kg ß = −0.11, p = 0.07 Monocytes ß = −0.6, p < 0.005 FT4 ß = 1.65, p < 0.01 |
Compound muscle action potential (CMAP) | R = 0.41, R2 = 0.16, p < 0.02 Height ß = 0.23, p < 0.05 Uric Acid ß = −1.7, p < 0.01 MCHC ß = −1.09, p < 0.02 FT4 ß = −7.75, p < 0.05 Eosinophiles ß = 5.93, p < 0.04 Calcium total ß = 7.6, p = 0.2 Diabetes duration ß = 3.9, p = 0.2 FT3 ß = −1.9, p = 0.02 | R = 0.48, R2 = 0.23, p < 0.00000 Weight z-score ß = −6.21, p < 0.0001 HbA1c mean ß = −0.9, p < 0.02 MCHC ß = −0.92, p < 0.04 FT3 ß = −3.4, p < 0.02 Monocytes ß = −2.8, p < 0.04 Creatinine ß = 6.6, p < 0.02 Microalbuminuria ß = 0.3, p < 0.005 Diabetes duration ß = 3.9, p = 0.2 |
Median Sensory Nerve | Sural Nerve | |
---|---|---|
Sensory nerve conduction velocity (SCV) | R = 0.47, R2 = 0.22, p < 0.00000 Height ß = −1.01, p < 0.0005 Weight ß = 1.17, p < 0.001 BMI ß = −3.25, p < 0.002 BID/kg ß = −10.3, p < 0.03 Eosinophiles ß = −4.15, p < 0.05 TSH ß = −0.92, p < 0.002 Duration of CSII ß = 0.18, p = 0.1 | R = 0.39, R2 = 0.15, p < 0.001 Height ß = 0.09, p < 0.005 Weight ß = −0.1, p < 0.02 BMI ß = −0.33, p < 0.001 BID/kg ß = −1.03, p < 0.05 WBC ß = −0.15, p < 0.05 Duration of CSII ß = −0.12, p = 0.4 NLR ß = −0.22, p = 0.15 |
Distal sensory latency (DSL) | R = 0.57, R2 = 0.33, p < 0.00000 Height ß = 0.06, p < 0.002 Weight ß = −0.06, p < 0.005 BMI ß = 0.17, p < 0.005 BID/kg ß = 0.55, p < 0.05 Neutrophiles ß = −0.2, p < 0.05 TSH ß = 0.02, p < 0.05 Duration of CSII ß = −0.1, p = 0.2 | R = 0.36, R2 = 0.13, p < 0.001 HbA1c mean ß = 0.07, p < 0.02 BMI z-score ß = −0.12, p < 0.02 TDI/kg ß = −1.28, p < 0.001 FT4 ß = 0.98, p < 0.01 FT3 ß = −0.07, p = 0.2 LDL cholesterol ß = −0.22, p = 0.08 Monocytes ß = −0.16, p = 0.2 |
Sensory nerve action potential amplitude (SNAP) | R = 0.52, R2 = 0.26, p < 0.00001 Height ß = −3.54, p < 0.01 BMI ß = −12.54, p < 0.005 BID/kg ß = −45.2, p < 0.05 Diabetes duration ß = 15.6, p < 0.05 Age at onset ß = 15.9, p < 0.05 Neutrophiles ß = 6.1, p < 0.02 PLT ß = 0.06, p < 0.03 FT4 ß = −19.8, p = 0.2 Monocytes ß = 8.3, p = 0.06 | R = 0.4, R2 = 0.16, p < 0.0001 Height ß = −0.37, p < 0.0001 BMI ß = −0.89, p < 0.001 BID/kg ß = −11.8, p = 0.2 Monocytes ß = −3.7, p = 0.2 Calcium total ß = 11.2, p = 0.3 Diabetes duration ß = −0.3, p = 0.1 |
Parameter | Mean+/−SD | Median | Min–Max |
---|---|---|---|
Age (years) | 17.93+/−0.2 | 18.0 | 16.5–18.0 |
Age at onset (years) | 10.29+/−4.17 | 10.66 | 1.17–17.19 |
Weight (kg) | 69.76+/−11.45 | 69.45 | 45.5–98 |
Height (cm) | 173.78+/−9.57 | 173.9 | 154–200 |
BMI (kg/m2) | 23.1+/−3.42 | 22.59 | 16.26–33.91 |
BMI Z-score | 0.44+/−1.02 | 0.48 | –2.42–2.67 |
Diabetes duration (years) | 7.58+/−4.16 | 7.21 | 0.65–16.94 |
Current HbA1c (%) | 8.07+/−1.74 | 7.8 | 5.2–15.6 |
Mean HbA1c (%) | 7.94+/−1.37 | 7.71 | 5.1–13.34 |
TDI (u) | 52.41+/−18.2 | 50.71 | 5.0–99.4 |
TDI/kg of weight (u/kg) | 0.75+/−0.23 | 0.75 | 0.09–1.35 |
BID (u) | 18.7+/−6.87 | 17.85 | 2.85–50 |
BID/kg of weight (u/kg) | 0.27+/−0.09 | 0.26 | 0.04–0.61 |
% of basal insulin | 36.45+/−8.62 | 36.17 | 8.81–60.0 |
Duration of CSII (years) | 6.01+/−3.52 | 5.83 | 0.01–15.15 |
Hemoglobin (g/L) | 14.55+/−1.5 | 14.6 | 5.7–17.4 |
MCHC (g/dL) | 33.84+/−1.14 | 33.7 | 31–37.4 |
WBC (10^3/uL) | 6.27+/−1.63 | 6.2 | 2–14 |
PLT (10^3/uL) | 257.99+/−60.68 | 263 | 25–408 |
Neutrophil (10^3/uL) | 3.31+/−1.39 | 3.02 | 1.17–11.4 |
Lymphocytes (10^3/uL) | 2.18+/−0.59 | 2.18 | 0.64–4.05 |
Monocytes (10^3/uL) | 0.57+/−0.35 | 0.54 | 0.12–4.3 |
Eosinophils (10^3/uL) | 0.2+/−0.18 | 0.14 | 0.02–1.32 |
NLR | 1.63+/−0.9 | 1.42 | 0.57–7.81 |
Cholesterol total (mg/dL) | 166.17+/−33.56 | 160 | 98–309 |
LDL cholesterol (mg/dL) | 88.02+/−27.77 | 84.8 | 36–187 |
HDL cholesterol (mg/dL) | 60.3+/−13.5 | 59 | 33–99 |
Triglycerides (mg/dL) | 91.99+/−61.9 | 78 | 30–615 |
Uric acid (mg/dL) | 4.32+/−0.99 | 4.15 | 2.2–6.8 |
Microalbuminuria (mg/L) | 13.6+/−38.74 | 6.95 | 3–500 |
Creatinine serum (mg/dL) | 0.81+/−0.19 | 0.81 | 0.39–2.26 |
Cystatin (mg/L) | 0.8+/−0.12 | 0.8 | 0.53–1.16 |
ALAT (U/L) | 14.23+/−9.42 | 12.0 | 5.0–67.0 |
Bilirubin total (mg/dL) | 0.84+/−0.47 | 0.72 | 0.16–2.91 |
25(OH)D3 vitamin (ng/mL) | 24.22+/−9.48 | 23.3 | 7.0–76.6 |
Calcium total (mmol/L) | 2.37+/−0.08 | 2.38 | 2.13–2.53 |
TSH (µU/mL) | 2.05+/−1.2 | 1.82 | 0.49–10.75 |
FT3 (pg/mL) | 2.93+/−0.48 | 2.97 | 0.81–4.02 |
FT4 (ng/dL) | 0.94+/−0.11 | 0.94 | 0.63–1.24 |
Cortisol (µg/dL) | 15.15+/−3.73 | 15.4 | 5.6–24.3 |
IgA (g/L) | 1.86+/−0.74 | 1.76 | 0.1–4.5 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wysocka-Mincewicz, M.; Baszyńska-Wilk, M.; Mazur, M.; Byczyńska, A.; Nowacka-Gotowiec, M. Thyroid Hormones, Peripheral White Blood Count, and Dose of Basal Insulin Are Associated with Changes in Nerve Conduction Studies in Adolescents with Type 1 Diabetes. Metabolites 2021, 11, 795. https://doi.org/10.3390/metabo11110795
Wysocka-Mincewicz M, Baszyńska-Wilk M, Mazur M, Byczyńska A, Nowacka-Gotowiec M. Thyroid Hormones, Peripheral White Blood Count, and Dose of Basal Insulin Are Associated with Changes in Nerve Conduction Studies in Adolescents with Type 1 Diabetes. Metabolites. 2021; 11(11):795. https://doi.org/10.3390/metabo11110795
Chicago/Turabian StyleWysocka-Mincewicz, Marta, Marta Baszyńska-Wilk, Maria Mazur, Aleksandra Byczyńska, and Monika Nowacka-Gotowiec. 2021. "Thyroid Hormones, Peripheral White Blood Count, and Dose of Basal Insulin Are Associated with Changes in Nerve Conduction Studies in Adolescents with Type 1 Diabetes" Metabolites 11, no. 11: 795. https://doi.org/10.3390/metabo11110795